<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04765267</url>
  </required_header>
  <id_info>
    <org_study_id>OMED 3-7-2</org_study_id>
    <nct_id>NCT04765267</nct_id>
  </id_info>
  <brief_title>Micronutrients in Management of Symptomatic Oral Lichen Planus</brief_title>
  <official_title>Evaluation of Micronutrients With Topical Corticosteroid Versus Topical Corticosteroid in Management of Symptomatic Oral Lichen Planus: Three-arm Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of oral lichen planus is challenging. Diverse therapeutic modalities have been&#xD;
      suggested, but a permanent cure is not yet available. In some OLP patients, topical&#xD;
      corticosteroid alone is not sufficiently enough, thus it may require a supplementation to&#xD;
      augment its effect. Micronutrients are gaining more attention as therapeutic modalities in&#xD;
      immunologic disorders. Researchers are recommended to conduct further clinical studies are to&#xD;
      assess the role of these elements in management of OLP (Gholizadeh &amp; Sheykhbahaei, 2020).&#xD;
      Among the less visited micronutrients are zinc and vitamin D. This trial will assess their&#xD;
      role in management of OLP.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The enrolled patients will be divided randomly into three groups. One group will receive&#xD;
      topical Corticosteroid (Kenacort A Orabase: triamcinolone acetonide 0.1% adhesive paste -&#xD;
      Dermapharm) four times daily, the second group will receive topical Corticosteroid (Kenacort&#xD;
      A Orabase: triamcinolone acetonide 0.1% adhesive paste - Dermapharm) four times daily with&#xD;
      systemic zinc (Octozinc: Zinc sulphate heptahydrate 25 mg tablets - October Pharma) twice&#xD;
      daily and the third group will receive topical Corticosteroid (Kenacort A Orabase:&#xD;
      triamcinolone acetonide 0.1% adhesive paste - Dermapharm) four times daily with systemic&#xD;
      vitamin D (Cholecalciferol: vitamin D3 15 ml oral solution - Medical Union Pharmaceuticals)&#xD;
      once daily. The patients will be recalled weekly for eight weeks. For every four weeks of&#xD;
      topical corticosteroid application, topical oral antifungal (Daktarin 2% oral gel -&#xD;
      miconazole) will be prescribed, four times daily for one week, to all the patients in the&#xD;
      trial, to avoid secondary infection with oral candidiasis. The patients will be asked to&#xD;
      prohibit the use of any topical or systemic medication during the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain intensity</measure>
    <time_frame>baseline (week 0), daily in week 1, week 1,week 2, week 3, week 4, week 5, week 6 and week 7</time_frame>
    <description>Visual analogue scale (0-10)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in clinical improvement</measure>
    <time_frame>baseline (week 0), week 1,week 2, week 3, week 4, week 5, week 6 and week 7</time_frame>
    <description>measured using Thongprasom et al. scoring system</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Oral Lichen Planus</condition>
  <arm_group>
    <arm_group_label>Topical Corticosteroid with Systemic Zinc.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Octozinc: Zinc sulphate heptahydrate 25 mg tablets - October Pharma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Corticosteroid with Systemic Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cholecalciferol: vitamin D3 15 ml oral solution - Medical Union Pharmaceuticals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Corticosteroid</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Kenacort A Orabase: triamcinolone acetonide 0.1% adhesive paste - Dermapharm</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc sulphate heptahydrate</intervention_name>
    <description>Dietary supplements</description>
    <arm_group_label>Topical Corticosteroid</arm_group_label>
    <arm_group_label>Topical Corticosteroid with Systemic Vitamin D</arm_group_label>
    <arm_group_label>Topical Corticosteroid with Systemic Zinc.</arm_group_label>
    <other_name>Cholecalciferol: vitamin D3 oral solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from erosive or atrophic OLP&#xD;
&#xD;
          -  Patients free from any visible oral lesions other than OLP.&#xD;
&#xD;
          -  Patients who agreed to take the supplied interventions.&#xD;
&#xD;
          -  Patient who will agree to participate in the study.&#xD;
&#xD;
          -  Patients who will accept to sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients suffering from any systemic disease.&#xD;
&#xD;
          -  Treatment with any systemic treatment such as systemic steroids, other&#xD;
             immunosuppressive drugs or non-steroidal anti-inflammatory drugs at least eight weeks.&#xD;
&#xD;
          -  Treatment with any oral topical medications for at least four weeks prior to the&#xD;
             study.&#xD;
&#xD;
          -  Pregnant and lactating mothers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>alaa a mohamed, assistant lecturer</last_name>
    <phone>+201005875212</phone>
    <email>alaa_shousha@dentistry.cu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Dentistry</name>
      <address>
        <city>Cairo</city>
        <zip>11728</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>alaa a mohamed</last_name>
      <phone>+201005875212</phone>
      <email>alaa_shousha@dentistry.cu.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Alaa Shousha</investigator_full_name>
    <investigator_title>Assistant Lecturer</investigator_title>
  </responsible_party>
  <keyword>micronutrients</keyword>
  <keyword>topical corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lichen Planus, Oral</mesh_term>
    <mesh_term>Lichen Planus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Zinc Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

